Skip Navigation

Europace 1999 1(1):8-13; doi:10.1053/eupc.1998.0014
© 1999 by European Society of Cardiology
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brignole, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brignole, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Report of a study group on ablate and pace therapy for paroxysmal atrial fibrillation*

M. Brignole, M. Gammage, L. Jordaens, R. Sutton on behalf of the Barcelona Discussion Group

Atrioventricular junctional (AVJ) catheter ablation followed by pacemaker implantation is now widely accepted for patients affected by paroxysmal atrial fibrillation (PAF) not controlled by antiarrhythmic drugs. However, few data exist on its indications, optimal methodology and complications. Therefore a study group examined current practice in Europe and North America, using a questionnaire, followed by a Study Group Meeting to discuss the results. Based upon this, class I, class II and class III indications were proposed. Class I indications (for which general agreement existed) include drug-refractory PAF, correlating with important symptoms, the bradycardia–tachycardia syndrome already treated with a pacemaker, and continued PAF. Large differences exist in the current methodology, but consensus was reached on the technical approaches of right and left-sided AVJ ablation, and on the timing of pacemaker implant in relation to ablation. No complete agreement was reached on technical features such as catheter choice and heparin use. The recommended pacing mode was DDDR with mode switching.

Key Words: Paroxysmal atrial fibrillation, atrioventricular junctional ablation, dual chamber pacing, mode switching

Correspondence: Dr Michael D. Gammage, Department of Cardiovascular Medicine, University of Birmingham and Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, U.K.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EuropaceHome page
T. R. Betts
Atrioventricular junction ablation and pacemaker implant for atrial fibrillation: still a valid treatment in appropriately selected patients
Europace, April 1, 2008; 10(4): 425 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
A. Capucci, G.Q. Villani, N. Marrazzo, and M. Piepoli
The complementary role of drug, ablation and device in the electrical therapy of atrial fibrillation
Eur. Heart J. Suppl., November 1, 2001; 3(suppl_P): P47 - P52.
[Abstract] [PDF]

Home page
 EuropaceHome page
L. Jordaens
How to make sure complications are avoided after an otherwise safe procedure
Europace, January 1, 2000; 2(3): 191 - 192.
[PDF]

Home page
 EuropaceHome page
S. Levy
Atrioventricular junctional ablation and pacing for paroxysmal atrial fibrillation: the Barcelona recommendations
Europace, January 1, 1999; 1(1): 2 - 4.
[PDF]

Home page
 EuropaceHome page
L. Kappenberger
Ablate and pace therapy for paroxysmal atrial fibrillation, too much too late
Europace, January 1, 1999; 1(1): 5 - 6.
[PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.